SoftBank-backed Vir Biotechnology's shares tumble in market debut
Share:
(Reuters) - Shares of SoftBank-backed Vir Biotechnology Inc plunged nearly 19.3% on their debut on Friday, adding to the gloom in the IPO market following WeWork's failed attempt to list on the stock market.Shares opened at $16.15 giving the biotech firm a market capitalisation of $1.77 billion.The San Francisco-based infectious disease researcher raised $142.9 million, selling its offering at $20 per share. It had set a price range of $20-$22 per share.Vir researches new therapies for..